Furthermore, ASOs have shown promising efficacy in targeting Huntington's gene (HTT) for Huntington's disease (HD), targeting SOD1 and C9ORF72 for amyotrophic lateral sclerosis (ALS), and targeting MAPT (TAU) for AD [187]. This evidence concerns the gene SOD1 and Huntington disease.